RxDoctor Payments Data

Bridget Jones, MD

Neurology · Jackson, MSNPI 1790040533

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 683 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations.

$13,708in general payments, 2019–2025

Across 683 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$779
  • Intuitive Surgical$760
  • SK Life Science, Inc.$752
  • Pfizer$717
  • UCB, Inc.$658
  • plus $9K from 52 others

What the payments were for

  • Speaking & faculty fees$1071%
  • Travel & lodging$7606%
  • Food & beverage$12,84194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)81$1,243
Teva Pharmaceuticals USA, Inc.50$779
Intuitive Surgical6$760
SK Life Science, Inc.37$752
Pfizer41$717
UCB, Inc.33$658
Lundbeck LLC33$634
Novartis30$633
Acadia Pharmaceuticals Inc34$616
Sanofi26$536
AstraZeneca23$529
Neurocrine Biosciences, Inc.14$362
Lilly USA, LLC24$341
Otsuka America Pharmaceutical, Inc.13$330
Merz Pharmaceuticals, LLC11$300
MDD US Operations, LLC12$280
Biogen12$245
Sunovion Pharmaceuticals Inc.14$244
CSL Behring10$227
Acorda Therapeutics, Inc10$222
Amgen(2 entities)11$198
Avanir Pharmaceuticals, Inc.13$195
Biohaven Pharmaceuticals, Inc.11$180
Impel Pharmaceuticals Inc.8$178
Amneal Pharmaceuticals LLC10$174
Medtronic3$172
Argenx US, Inc.7$164
Genentech USA, Inc.11$152
Catalyst Pharmaceuticals, Inc.7$145
Biohaven Pharmaceutical Holding Company Ltd.7$137
Adamas Pharmaceuticals, Inc.6$124
Mallinckrodt Hospital Products Inc.4$105
Corium, LLC7$104
Neurelis, Inc.4$103
Eisai Inc.4$101
Takeda Pharmaceuticals U.S.A., Inc.5$100
Upsher-smith Laboratories LLC6$89
Axsome Therapeutics, Inc.4$89
EMD Serono, Inc.5$79
Kyowa Kirin, Inc.3$70
Greenwich Biosciences, Inc.3$63
Assertio Therapeutics, Inc.4$58
ANI Pharmaceuticals, Inc.3$56
Johnson & Johnson(2 entities)3$56
Sanofi-aventis U.S. LLC3$55
Grifols USA, LLC3$48
Sumitomo Pharma America, Inc.2$44
Xeris Pharmaceuticals, Inc.2$34
Mylan Specialty L.p.1$33
Convatec Inc.1$30
Jazz Pharmaceuticals Inc.1$27
Alnylam Pharmaceuticals Inc.1$26
Si-bone, Inc.1$24
Medline Industries LP1$24
Boston Scientific1$20
Abbott1$15
E.r. Squibb & Sons, L.L.C.1$14
Bristol Myers Squibb1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,708 in reported general payments places this provider in the 70th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$71,773
Medicare patients
414
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate13$70,789
Memantine Hcl1,043$27,448
Rivastigmine121$24,714
TrintellixVortioxetine Hydrobromide15$11,747
RivastigmineRivastigmine Tartrate233$11,202
Donepezil Hcl800$10,902
Entacapone38$6,516
Duloxetine Hcl243$5,092
Levetiracetam102$3,564
Sertraline Hcl340$3,368
Carbidopa-LevodopaCarbidopa/Levodopa106$2,674
Rasagiline Mesylate15$2,241
Lacosamide30$2,022
Carbidopa-Levodopa ErCarbidopa/Levodopa30$1,845
Oxcarbazepine23$1,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$616$70,78913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$100$11,74715 claims
Upsher-smith Laboratories LLCTopiramate$89$22526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 neurology providers in Mississippi.

Other neurology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →